Actualités

Healthcare stocks were higher Tuesday afternoon, with the NYSE Healthcare Index rising 0.4% and the

Novo Nordisk (NVO) on Tuesday sued rival Eli Lilly (LLY) in the US over alleged "misleading" adverti

In a lawsuit filed in the US, Novo alleged that Lilly’s campaign was designed to mislead consumers on “comparative efficacy” of drug brands.

(Updates with Eli Lilly's response in the fifth and sixth paragraphs.) Novo Nordisk (NVO) said Tu

The European markets closed higher Tuesday as tech, bank, and mining stocks rallied, while investors

All three major US stock indexes were up in late-morning trading Tuesday, as investors focused on so

The Danish drugmaker alleges Lilly used outdated trial data to claim Zepbound beats Wegovy on weight loss

Novo Nordisk (NYSE:NVO) has filed a federal lawsuit against Eli Lilly, alleging that its rival’s advertising campaigns for blockbuster GLP-1 obesity and diabetes drugs mislead consumers about the effectiveness of competing treatments. The complaint, filed on July 21, 2026, in the US District...

The lawsuit alleges that Eli Lilly misled consumers by using outdated clinical trial data to make its drugs appear more effective than Novo's.

Novo Nordisk alleges Eli Lilly falsely advertised Zepbound and Mounjaro by claiming the drugs outperform Wegovy and Ozempic.

Novo Nordisk (NVO) is suing Eli Lilly (LLY) for misleading advertising. Morning Brief host Julie Hyman discusses the details with Yahoo Finance Breaking Business News Reporter Jake Conley and Payne Capital Management president Ryan Payne.

Drugmakers clash over marketing of blockbuster obesity and diabetes treatmentsNovo Nordisk Inc. (NYSE:NVO) has filed a lawsuit against Eli Lilly and Company (NYSE:LLY) and Lilly USA, LLC, accusing its rival of false advertising and unfair competition in a dispute over marketing claims for their leading GLP-1 medicines.

Agios Pharmaceuticals dropped its next-generation sickle cell drug Tuesday after a failed Phase 2 study. Agios stock tumbled.

Novo Nordisk is offering an attractive 3.5% yield backed by a business where volume is the new focus.

Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.

Danish pharmaceuticals heavyweight Novo Nordisk said Tuesday it is suing its arch US rival, Eli Lilly, over "false and materially misleading" adverts for their competing weight-loss and anti-diabetes treatments. Novo Nordisk has developed a molecule called semaglutide, while Eli Lilly developed rival molecule tirzepatide. 

Novo alleges that Lilly’s Zepbound advertisements compare the drug’s highest approved dose with lower doses of Wegovy.

Investing.com -- The clash between pharma titans Novo Nordisk and Eli Lilly just escalated from the pharmacy counter to the courtroom. Novo Nordisk Inc. filed a lawsuit in the U.S. District Court for the District of New Jersey against Eli Lilly and Company and Lilly USA, LLC, alleging multiple violations of federal and state false advertising and unfair competition laws under the Lanham Act. The lawsuit takes aim at Lilly’s aggressive direct-to-consumer (DTC) advertising campaigns for its blockb

Novo Nordisk claims Eli Lilly aired misleading ads comparing the pharma companies' respective weight-loss drugs, Wegovy and Zepbound.

The maker of Ozempic and Wegovy says its competitor is misleading consumers by citing outdated weight-loss data in advertisements.

Novo says Lilly's TV and social media campaigns cite outdated trial data to make Zepbound and Mounjaro look more effective than rival injections

By Maggie Fick LONDON, July 21 (Reuters) - Novo Nordisk said on Tuesday it was suing rival Eli Lilly in U.S. federal court, accusing the U.S. drugmaker of false advertising in claiming its weight-loss

(Bloomberg) -- Novo Nordisk A/S is suing Eli Lilly & Co. in US federal court, claiming that Lilly’s advertising for its blockbuster obesity shot Zepbound and diabetes injection Mounjaro is misleading as competition between the two drugmakers escalates.Most Read from BloombergYemen’s Houthis to Impose Maritime Blockade on Saudi ArabiaChina AI Sensation Moonshot’s Gamble on Big Models Pays OffTrump Vows 50% Tariff on Canadian Goods Using Depression-Era LawMoonshot’s Kimi K3 May Be More About Memor

Novo Nordisk has accused arch-rival Eli Lilly of peddling false claims about its weight-loss products in advertising campaigns, marking the latest...

The temperature was 92 degrees Fahrenheit. The sweat, profuse. And I was walking toward an exhibition about the “obesity experience” on London’s bustling riverside funded by a $220 billion pharmaceutical company.

Novo Nordisk (CPSE:NOVO B) and Fangzhou have launched Kyinsu®, the world's first once weekly basal insulin/GLP-1 RA combination therapy, in China. The product is being introduced through Fangzhou's AI driven Internet hospital, targeting broader access for people living with diabetes. The launch expands Novo Nordisk's presence in China by pairing a new treatment format with a digital care platform. Novo Nordisk, trading at DKK329.9 per share, is adding Kyinsu® to its portfolio at a time when...

Novo Nordisk wins EU approval for the first GLP-1 obesity tablet, expanding Wegovy's reach, but tougher competition keeps the broader investment outlook in focus.

Citi has raised its price target on Novo Nordisk (NYSE:NVO) to DKK330 ahead of second-quarter results on 5 August, citing the strength of the Danish drugmaker's Wegovy pill launch. The broker lifted its 2026 sales and operating income estimates by 4% to 5%, and its earnings per share...

The European Commission approved Novo Nordisk A/S’ Wegovy pill, a once-daily oral semaglutide 25 mg treatment for adults with obesity or overweight with at least one weight-related comorbidity. The approval makes Wegovy the first GLP-1 receptor agonist available in tablet...

Viking's latest program seeks to push the envelope in weight loss efficacy.